Jounce Therapeutics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Friday, August 7, 2020
Jounce Therapeutics (NASDAQ: JNCE) will report its second quarter 2020 financial results and provide a corporate update on August 7, 2020, before market open. The management team will host a live conference call and webcast at 8:00 a.m. ET. Investors can access the conference by dialing domestic (866) 916-3380 or international (210) 874-7772 using conference ID 3898328. Jounce is focused on developing novel cancer immunotherapies, with key programs including vopratelimab in Phase 2 trials and JTX-4014, a PD-1 inhibitor.
- Jounce has four development-stage programs, including two in clinical stages.
- Vopratelimab is currently in a Phase 2 clinical trial EMERGE.
- Plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection.
- None.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2020 financial results and provide a corporate update before market open on Friday, August 7, 2020. Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00 a.m. ET.
Conference Call and Webcast
To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 3898328. The live webcast can be accessed under “Events & Presentations” in the Investors and Media section of the company’s website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounce’s IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist, and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. For more information, please visit www.jouncetx.com.
Investor Contact:
Komal Joshi
Jounce Therapeutics, Inc.
(857) 320-2523
kjoshi@jouncetx.com
FAQ
What are the upcoming events for Jounce Therapeutics on August 7, 2020?
How can I access the Jounce Therapeutics conference call?
What is the focus of Jounce Therapeutics?
